Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Takeda M, Homma Y, Araki I, Kakizaki H, Yamanishi T, Yokota T, Gotoh M, Igawa Y, Seki N, Takei M, Yoshida M, Sugaya K, Nishizawa O; Japanese Naftopidil Neurogenic Lower Urinary Tract Dysfunction Study Group. Takeda M, et al. Among authors: yoshida m. BJU Int. 2011 Jul;108(1):100-7. doi: 10.1111/j.1464-410X.2010.09682.x. Epub 2010 Nov 9. BJU Int. 2011. PMID: 21062392 Clinical Trial.
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group. Yamaguchi O, et al. Among authors: yoshida m. BJU Int. 2007 Sep;100(3):579-87. doi: 10.1111/j.1464-410X.2007.07031.x. BJU Int. 2007. PMID: 17669143 Clinical Trial.
Clinical guideline for male lower urinary tract symptoms.
Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshida M; Japanese Society of Neurogenic Bladder. Homma Y, et al. Among authors: yoshida m. Int J Urol. 2009 Oct;16(10):775-90. doi: 10.1111/j.1442-2042.2009.02369.x. Int J Urol. 2009. PMID: 19811547
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Ikeda Y, Ohkawa S. Yamaguchi O, et al. Among authors: yoshida m. BJU Int. 2014 Jun;113(6):951-60. doi: 10.1111/bju.12649. Epub 2014 Mar 17. BJU Int. 2014. PMID: 24471907 Clinical Trial.
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. Among authors: yoshida m. BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23. BJU Int. 2015. PMID: 25639296 Clinical Trial.
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Yoshida M, et al. BJU Int. 2020 May;125(5):709-717. doi: 10.1111/bju.15020. Epub 2020 Feb 23. BJU Int. 2020. PMID: 31991511 Free PMC article. Clinical Trial.
10,901 results
You have reached the last available page of results. Please see the User Guide for more information.